Exelixis, Inc. (EXEL)
56.12
-1.31
(-2.28%)
USD |
NASDAQ |
Sep 11, 16:00
56.14
+0.02
(+0.04%)
After-Hours: 20:00
Exelixis Enterprise Value : 13.29B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 13.29B |
| September 10, 2026 | 13.62B |
| September 09, 2026 | 13.84B |
| September 08, 2026 | 13.68B |
| September 04, 2026 | 14.01B |
| September 03, 2026 | 14.04B |
| September 02, 2026 | 13.89B |
| September 01, 2026 | 13.49B |
| August 31, 2026 | 12.93B |
| August 28, 2026 | 12.88B |
| August 27, 2026 | 13.08B |
| August 26, 2026 | 13.29B |
| August 25, 2026 | 13.44B |
| August 24, 2026 | 12.90B |
| August 21, 2026 | 12.79B |
| August 20, 2026 | 12.69B |
| August 19, 2026 | 12.86B |
| August 18, 2026 | 12.55B |
| August 17, 2026 | 12.35B |
| August 14, 2026 | 12.08B |
| August 13, 2026 | 11.92B |
| August 12, 2026 | 11.87B |
| August 11, 2026 | 12.10B |
| August 10, 2026 | 12.51B |
| August 07, 2026 | 12.78B |
| Date | Value |
|---|---|
| August 06, 2026 | 12.32B |
| August 05, 2026 | 13.44B |
| August 04, 2026 | 13.26B |
| August 03, 2026 | 13.03B |
| July 31, 2026 | 12.52B |
| July 30, 2026 | 13.26B |
| July 29, 2026 | 13.10B |
| July 28, 2026 | 13.39B |
| July 27, 2026 | 13.22B |
| July 24, 2026 | 13.11B |
| July 23, 2026 | 13.18B |
| July 22, 2026 | 13.01B |
| July 21, 2026 | 13.29B |
| July 20, 2026 | 13.15B |
| July 17, 2026 | 13.24B |
| July 16, 2026 | 13.18B |
| July 15, 2026 | 13.15B |
| July 14, 2026 | 13.21B |
| July 13, 2026 | 13.27B |
| July 10, 2026 | 13.39B |
| July 09, 2026 | 13.54B |
| July 08, 2026 | 13.29B |
| July 07, 2026 | 13.53B |
| July 06, 2026 | 13.15B |
| July 02, 2026 | 13.23B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 32.94B |
| BioMarin Pharmaceutical, Inc. | 16.06B |
| Cytokinetics, Inc. | 10.34B |
| Emergent BioSolutions, Inc. | 766.90M |
| Gilead Sciences, Inc. | 199.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 212.05M |
| Revenue (Quarterly) | 628.69M |
| Total Expenses (Quarterly) | 416.64M |
| EPS Diluted (Quarterly) | 0.8166 |
| Gross Profit Margin (Quarterly) | 96.71% |
| Profit Margin (Quarterly) | 33.73% |
| Earnings Yield | 5.67% |
| Operating Earnings Yield | 6.54% |
| Normalized Earnings Yield | 5.765 |